HRP20161712T1 - Sol fotosenzibilizirajućeg agensa za uporabu u fotokemijskoj internalizaciji - Google Patents
Sol fotosenzibilizirajućeg agensa za uporabu u fotokemijskoj internalizaciji Download PDFInfo
- Publication number
- HRP20161712T1 HRP20161712T1 HRP20161712TT HRP20161712T HRP20161712T1 HR P20161712 T1 HRP20161712 T1 HR P20161712T1 HR P20161712T T HRP20161712T T HR P20161712TT HR P20161712 T HRP20161712 T HR P20161712T HR P20161712 T1 HRP20161712 T1 HR P20161712T1
- Authority
- HR
- Croatia
- Prior art keywords
- salt
- pharmaceutically acceptable
- therapeutic agent
- agent
- photosensitizing agent
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 13
- 239000003504 photosensitizing agent Substances 0.000 title claims 10
- 239000003814 drug Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical group N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002169 ethanolamines Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical class OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims 1
- 229940124856 vaccine component Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (15)
1. Farmaceutski prihvatljiva sol amfifilnog fotosenzibilizajućeg agensa za uporabu u metodi fotokemijske internalizacije, gdje je navedena sol bis(monoetanolamin) sol mezo-tetrafenil klor sulfonata (TPCS2a).
2. Bis(monoetanolamin) sol mezo-tetrafenil klor sulfonata (TPCS2a).
3. Farmaceutski sastav koji sadrži sol u skladu s patentnim zahtjevom 2, zajedno s barem jednim farmaceutski prihvatljivim nosačem ili ekscipijensom.
4. Proizvod koji sadrži farmaceutski prihvatljivu sol amfifilnog fotosenzibilizirajućeg agensa kako je definirano u patentnom zahtjevu 1, zajedno s terapijskim agensom za istovremenu, zasebnu ili sekvencijalnu uporabu u metodi fotokemijske internalizaciije.
5. Komplet za uporabu u metodi fotokemijske internalizacije sadrži:
(a) prvi spremnik koji sadrži farmaceutski prihvatljivu sol amfifilnog fotosenzibilizirajućeg agensa kako je definirano u patentnom zahtjevu 1;
(b) drugi spremnik koji sadrži terapijski agens; i
(c) ako je navedena sol u čvrstom obliku, treći spremnik koji sadrži vodenu otopinu za otapanje soli prije uporabe.
6. Farmaceutski sastav koji sadrži farmaceutski prihvatljivu sol amfifilnog fotosenzibilizirajućeg agensa kako je definirano u patentnom zahtjevu 1, zajedno s terapijskim agensom.
7. Farmaceutski sastav koji sadrži farmaceutski prihvatljivu sol amfifilnog fotosenzibilizirajućeg agensa kako je definirano u patentnom zahtjevu 1, zajedno s terapijskim agensom, za uporabu u liječenju.
8. Farmaceutski sastav u skladu s patentnim zahtjevom 7, za uporabu u liječenju raka, genskoj ili oligonukleotidnoj terapiji.
9. Farmaceutski sastav u skladu s patentnim zahtjevom 7 za uporabu u liječenju sa siRNA.
10. Uporaba farmaceutski prihvatljive soli amfifilnog fotosenzibilizirajućeg agensa kako je definirano u patentnom zahtjevu 1 i/ili terapijskog agensa za pripravu lijeka za uporabu u liječenju u kojem navedena sol fotosenzibilizirajućeg agensa i navedenog terapijskog agensa dolaze u dodir sa stanicama ili tkivima pacijenta bilo zasebno, istovremeno ili redom i navedene stanice ili tkiva se zrače svjetlom valne duljine učinkovite za aktiviranje navedenog fotosenzibilizirajućeg agensa.
11. Uporaba u skladu s patentnim zahtjevom 10, pri čemu je navedeno liječenje raka, genska ili oligonukleotidna terapiji.
12. Uporaba u skladu s patentnim zahtjevom 10, pri čemu je navedeno liječenje sa siRNA.
13. Uporaba farmaceutski prihvatljive soli amfifilnog fotosenzibilizirajućeg agensa kako je definirano u patentnom zahtjevu 1 za pripravu terapijskog agensa za uporabu u metodi fotokemijske internalizacije.
14. Proizvod, komplet, sastav ili uporaba u skladu s bilo kojim od patentnih zahtjeva 4 do 10, pri čemu je navedeni terapijski agens bleomicin.
15. Proizvod, komplet, sastav ili uporaba u skladu s bilo kojim od patentnih zahtjeva 4 do 10, pri čemu navedeni terapijski agens sadrži komponentu cjepiva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0914287.8A GB0914287D0 (en) | 2009-08-14 | 2009-08-14 | Compositions |
| EP10747249.0A EP2464384B1 (en) | 2009-08-14 | 2010-08-16 | Salt of a photosensitizing agent for use in photochemical internalization |
| PCT/GB2010/001547 WO2011018635A2 (en) | 2009-08-14 | 2010-08-16 | Photosensitizing compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161712T1 true HRP20161712T1 (hr) | 2017-04-21 |
Family
ID=41171444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161712TT HRP20161712T1 (hr) | 2009-08-14 | 2016-12-13 | Sol fotosenzibilizirajućeg agensa za uporabu u fotokemijskoj internalizaciji |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9026203B2 (hr) |
| EP (1) | EP2464384B1 (hr) |
| JP (1) | JP5946407B2 (hr) |
| KR (1) | KR101795362B1 (hr) |
| CN (1) | CN102648004B (hr) |
| AU (1) | AU2010283565B2 (hr) |
| BR (1) | BR112012003283B1 (hr) |
| CA (1) | CA2771021C (hr) |
| DK (1) | DK2464384T3 (hr) |
| ES (1) | ES2610143T3 (hr) |
| GB (1) | GB0914287D0 (hr) |
| HR (1) | HRP20161712T1 (hr) |
| LT (1) | LT2464384T (hr) |
| ME (1) | ME02616B (hr) |
| MX (1) | MX337481B (hr) |
| NZ (1) | NZ598380A (hr) |
| PL (1) | PL2464384T3 (hr) |
| PT (1) | PT2464384T (hr) |
| RS (1) | RS55530B1 (hr) |
| RU (1) | RU2574019C2 (hr) |
| SG (1) | SG178420A1 (hr) |
| SI (1) | SI2464384T1 (hr) |
| WO (1) | WO2011018635A2 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0914287D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Compositions |
| GB0914286D0 (en) * | 2009-08-14 | 2009-09-30 | Pci Biotech As | Method |
| US9693957B2 (en) | 2011-07-08 | 2017-07-04 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| GB201208548D0 (en) | 2012-05-15 | 2012-06-27 | Pci Biotech As | Compound and method |
| WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| EP3038619B1 (en) * | 2013-08-28 | 2023-10-04 | PCI Biotech AS | Compound and method for vaccination and immunisation |
| US10206871B2 (en) | 2014-10-14 | 2019-02-19 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof |
| US10806694B2 (en) | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
| GB201503776D0 (en) | 2015-03-05 | 2015-04-22 | Pci Biotech As | Compound and method |
| KR101736149B1 (ko) * | 2015-09-30 | 2017-05-17 | (주)나노팜 | 여드름 피부개선을 위한 광민감성 물질을 함유한 건식다중캡슐형 조성물 및 그의 제조방법 |
| CN109310702A (zh) | 2016-05-20 | 2019-02-05 | 芝加哥大学 | 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒 |
| RU2019109682A (ru) | 2016-10-14 | 2020-11-16 | ПиСиАй БИОТЕК АС | Лечение холангиокарциномы с применением tpcs-2-индуцированной фотохимической интернализации гемцитабина |
| CN111194232B (zh) | 2017-08-02 | 2023-01-31 | 芝加哥大学 | 纳米级金属有机层和金属有机纳米片 |
| CN107722075A (zh) * | 2017-10-09 | 2018-02-23 | 大连理工大学 | 一类二氢卟吩葡萄糖苷类化合物及其制备方法与应用 |
| GB201718631D0 (en) | 2017-11-10 | 2017-12-27 | Pci Biotech As | Method |
| RU2720799C1 (ru) * | 2019-07-03 | 2020-05-13 | Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" | Способ определения фракционного состава сульфированного фталоцианина алюминия |
| RU2757936C1 (ru) * | 2021-03-12 | 2021-10-25 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ прогнозирования риска развития хронической истинной экземы на основе молекулярно-генетических данных |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582831A (en) * | 1984-11-16 | 1986-04-15 | Pfizer Inc. | Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor |
| JPH0753861B2 (ja) * | 1985-04-15 | 1995-06-07 | 味の素株式会社 | 紫外線吸収剤 |
| US5284647A (en) | 1988-03-18 | 1994-02-08 | Schering Aktiengesellschaft | Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them |
| US5292516A (en) | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
| US5346703A (en) | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| IT1254045B (it) * | 1991-12-31 | 1995-09-06 | Lifegroup Spa | Derivati idrosolubili della biotina e relative composizioni terapeutiche |
| US5389681A (en) | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
| FR2700543B1 (fr) * | 1993-01-15 | 1995-03-17 | Synthelabo | Sels de dérivés de 4-pyrimidinone, leur préparation et leur application en thérapeutique. |
| DE4305523A1 (de) | 1993-02-17 | 1994-08-18 | Diagnostikforschung Inst | Meso-Tetraphenylporphyrin-Komplexverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
| NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| US6540981B2 (en) | 1997-12-04 | 2003-04-01 | Amersham Health As | Light imaging contrast agents |
| US6992107B1 (en) | 1995-03-10 | 2006-01-31 | Photocure Asa | Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy |
| DE69817529T2 (de) | 1998-02-19 | 2004-06-24 | Microflow Engineering S.A. | Vorrichtung und Gerät zur intrakavitären Wirkstofffreigabe während videounterstützter Chirurgie oder anderer endoskopischer Verfahren |
| GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
| US6398748B1 (en) | 1999-03-16 | 2002-06-04 | Robert B. Wilson | Splint bandage and method |
| US6570013B2 (en) * | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| KR20030074633A (ko) | 2000-11-29 | 2003-09-19 | 피씨아이 바이오테크 에이에스 | 사이토졸 내로의 바이러스 매개된 분자 전달을 위한광화학적 내부이행 |
| WO2002044396A1 (en) | 2000-11-29 | 2002-06-06 | Pci Biotech As | Photochemical internalization for delivery of molecules into the cytosol |
| GB0118251D0 (en) | 2001-07-26 | 2001-09-19 | Photocure Asa | Method |
| GB0121023D0 (en) | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
| CN1823038B (zh) | 2003-05-14 | 2010-05-12 | 索科普哈应用研究产品商业化公司-健康与人类科学Sec | 双亲性三磺酸化四氮杂卟啉在医药中的光动力学应用 |
| GB0415263D0 (en) | 2004-07-07 | 2004-08-11 | Norwegian Radium Hospital Res | Method |
| GB2420784A (en) | 2004-11-25 | 2006-06-07 | Pci Biotech As | Phototherapeutic amphiphilic phthalocyanine-based compounds where 1 peripheral ring system is more hydrophilic & has more hydrophilic groups than the other 3 |
| GB0514743D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Salt |
| ES2400091T3 (es) | 2005-08-11 | 2013-04-05 | Massachusetts Institute Of Technology | Dispositivo de suministro de fármacos intravesical y método |
| GB0605743D0 (en) * | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
| JP2008095050A (ja) | 2006-10-16 | 2008-04-24 | Hidetoshi Tsuchida | アルブミン−金属ポルフィリン複合体および光増感剤 |
| GB0811955D0 (en) | 2008-06-30 | 2008-07-30 | Pci Biotech As | Method |
| GB0914286D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Method |
| GB0914287D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Compositions |
-
2009
- 2009-08-14 GB GBGB0914287.8A patent/GB0914287D0/en not_active Ceased
-
2010
- 2010-08-16 NZ NZ598380A patent/NZ598380A/en unknown
- 2010-08-16 BR BR112012003283-6A patent/BR112012003283B1/pt active IP Right Grant
- 2010-08-16 WO PCT/GB2010/001547 patent/WO2011018635A2/en active Application Filing
- 2010-08-16 AU AU2010283565A patent/AU2010283565B2/en active Active
- 2010-08-16 JP JP2012524278A patent/JP5946407B2/ja active Active
- 2010-08-16 DK DK10747249.0T patent/DK2464384T3/en active
- 2010-08-16 MX MX2012001953A patent/MX337481B/es active IP Right Grant
- 2010-08-16 RS RS20161158A patent/RS55530B1/sr unknown
- 2010-08-16 KR KR1020127006572A patent/KR101795362B1/ko active IP Right Grant
- 2010-08-16 EP EP10747249.0A patent/EP2464384B1/en active Active
- 2010-08-16 PL PL10747249T patent/PL2464384T3/pl unknown
- 2010-08-16 ME MEP-2016-294A patent/ME02616B/me unknown
- 2010-08-16 SI SI201031359A patent/SI2464384T1/sl unknown
- 2010-08-16 US US13/390,404 patent/US9026203B2/en active Active
- 2010-08-16 CA CA2771021A patent/CA2771021C/en active Active
- 2010-08-16 RU RU2012109559/15A patent/RU2574019C2/ru active
- 2010-08-16 ES ES10747249.0T patent/ES2610143T3/es active Active
- 2010-08-16 SG SG2012010385A patent/SG178420A1/en unknown
- 2010-08-16 CN CN201080046459.5A patent/CN102648004B/zh active Active
- 2010-08-16 LT LTEP10747249.0T patent/LT2464384T/lt unknown
- 2010-08-16 PT PT107472490T patent/PT2464384T/pt unknown
-
2016
- 2016-12-13 HR HRP20161712TT patent/HRP20161712T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161712T1 (hr) | Sol fotosenzibilizirajućeg agensa za uporabu u fotokemijskoj internalizaciji | |
| Kurakula et al. | Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition | |
| Zhang et al. | Targeted chemo-photodynamic combination platform based on the DOX prodrug nanoparticles for enhanced cancer therapy | |
| Han et al. | Oxygen-independent combined photothermal/photodynamic therapy delivered by tumor acidity-responsive polymeric micelles | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
| WO2007040469A3 (en) | Chloroquine coupled compositions and methods for their synthesis | |
| BR112013010853A2 (pt) | "agentes citotóxicos compreendendo derivados de ansamitocina, composição farmacêutica e uso destes" | |
| NO20075136L (no) | Nye liposompreparater | |
| ME00199B (me) | Gastrorezistentne farmaceutske formulacije koje sadrže rifaksimin | |
| JP2013501769A5 (hr) | ||
| UY30438A1 (es) | Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos | |
| RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
| UY28271A1 (es) | Compuestos químicos | |
| ECSP078014A (es) | Regimen de dosificacion para prasugrel | |
| JP2016027036A (ja) | 外用組成物、化粧料、経皮吸収促進用組成物、外用組成物における有効成分の経皮吸収性を高める方法、経皮投与型医薬及び点眼用組成物 | |
| Shinde et al. | Natural and synthetic functional materials for broad spectrum applications in antimicrobials, antivirals and cosmetics | |
| US9144670B2 (en) | External preparation kit | |
| CY1118181T1 (el) | Αναβραζοντα δισκια για χρηση σε εισπνοες | |
| Ye et al. | Targeted photodynamic therapy with a novel photosensitizer cercosporin encapsulated multifunctional copolymer | |
| Ren et al. | Stereocomplex Crystallized Nanomedical System for Enhanced Type I PDT and Synergistic Chemo-Phototherapy | |
| ES2469240B1 (es) | Uso de un agente fotosensible capaz de producir especies reactivas de oxígeno en la preparación de un medicamento útil para la terapia fotodinámica de una enfermedad relacionada con células madre, uso "in vitro" y composición farmacéutica. | |
| Lai et al. | Rational design of a minimum nanoplatform for maximizing therapeutic potency: Three birds with one stone | |
| EA201070626A1 (ru) | Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества | |
| HRP20151241T1 (hr) | Upotreba s-adenozilmetionina (sam) i superoksid-dismutaze (sod) za pripravu lijekova za lijeäśenje alzheimerove bolesti |